BIOA

BioAge Labs is a pre-revenue clinical-stage biopharmaceutical company whose entire equity story rests on BGE-102, a novel oral NLRP3 inhibitor that only entered Phase 1 SAD/MAD dosing in late 2025. The FY2025 financials confirm the binary nature of the bet: $8.99M of revenue (almost certainly collaboration/grant income, not product sales) against a $80.6M net loss, a -$92.8M operating loss, and -$81.6M of operating cash burn that worsened 58.4% year-over-year. R&D rose 25.3% to $74.0M, which is the right direction for a developmental biotech but accelerates the cash drain.

The balance sheet is the one redeeming feature — $189M cash, only $2.65M of current debt, zero long-term debt, and $272M of equity — but cash fell 46.7% YoY and at the current burn rate provides roughly two years of runway before another dilutive raise. Share count is already up 23.8% YoY to 44.4M, and accumulated deficit deepened 31.9% to -$333M, telegraphing that further equity issuance is the financing path. Valuation is the dealbreaker: a $1.01B market cap on $8.99M of non-product revenue is 112x sales, and the company's own forward-looking language flags 'sufficiency of our cash, cash equivalents and marketable securities' and reliance on 'our ability to obtain and maintain regulatory approvals' as material risks — i.e. the price already discounts a clinical and regulatory outcome that has not been demonstrated.